Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) just unveiled an update.
CSL Limited announced the cessation of 7,194 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact CSL’s issued capital structure and reflects the company’s ongoing adjustments to its financial and operational strategies.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative medicines that save lives and improve the quality of life for people with rare and serious diseases. The company is a global leader in plasma-derived therapies and influenza vaccines, with a strong market presence in these areas.
YTD Price Performance: -13.10%
Average Trading Volume: 854,234
Technical Sentiment Signal: Sell
Current Market Cap: A$117.5B
See more data about CSL stock on TipRanks’ Stock Analysis page.